Runners and riders in the Covid vaccine race

Pfizer, AstraZeneca and Moderna have won acceptance for their Covid vaccines from the United kingdom regulator and the jabs are currently getting rolled out. But what about the other vaccine candidates and how quickly will they come to current market?

Our record gives a snapshot of what the vaccine landscape seems like.

The life sciences industry’s reaction to the pandemic has been unprecedented equally in phrases of the velocity at which it has developed vaccines and its willingness to collaborate with rivals. That has resulted in 237 potential vaccines, of which 64 are in human medical trials.

That’s good news as, in the vaccines business there is generally no “just one-dimension-fits-all” solution, with distinct countries necessitating distinct kinds of vaccines centered on a variety of variables which include local climate, land mass and demography. In other terms: there is a good deal of place in the current market for additional than just one vaccine.

Covid vaccines approved by the United kingdom

Pfizer/BioNtech

United kingdom acceptance day: December 2, 2020

Doses: 2

Efficacy: 90pc +

Kind: mRNA

Doses marketed or pre-ordered globally: The whole sum is undisclosed, but we know it has 300m on purchase from the EU and 200m from the US, which, jointly with the United kingdom, brings the whole to 540m

Doses procured by the United kingdom: 40m

Production capacity: Up to 2bn doses this 12 months